Join our daily newsletter At The Bell to receive exclusive market insights
ASX futures were largely flat near 8:30 AEDT, up only 0.08 per cent (6pts). The ASX200 could go either way.
The S&P 500 finished down 0.20 per cent; the NASDAQ down 0.07 per cent.
Looking at Australian economic data, we get retail trade this morning at 11:30 am AEDT.
On Wednesday, we get the monthly Australian inflation data for October, also at 11:30 am AEDT. Later that evening, we get the US PCE inflation data.
The figures contained within today’s and tomorrow’s releases from the ABS will be instrumental for the RBA at its next interest rate meeting on Tuesday, December 5.
Michele Bullock has noted that domestic ‘homegrown’ inflation remains too high.
This evening Australian time, we also get a raft of data from the US – including key Conference Board US consumer confidence data.
Here’s which stocks are attracting attention this morning:
Imugene (ASX:IMU) has been awarded fast-track designation by the US health regulator FDA.
That designation relates to the use of Imugene’s VAXINA in a study on Bile Duct Cancer patients.
The FDA will now help expedite the program.
Shares last traded at 9.1 cents.
In the materials space, Metals Australia (ASX:MLS) has confirmed a new pegmatite find.
Assay results for 63 samples from 21 pegmatite outcrops remain pending.
The pegmatites are located 2.5 kilometres away from Patriot Battery Metals’ (PMT) acreage in James Bay.
Shares last traded at 3.6 cents.
Newpeak Metals (ASX:NPM) has confirmed its termination of a proposed SCB transaction.
Back in June, New Peak and Southern Cross Brittania fired up a business relationship – one now sent to the dustbin.
SCB has repaid Newpeak a US$20,000 deposit it made.
Shares last traded at 0.1 cents.
Meanwhile, Critical Resources (ASX:CRR) has flagged that ore sorting test work is to begin.
The ore sorting will assist beneficiation and optimisation studies progress.
Multiple parties will assist Critical with the downstream test work; the previous test work has produced 5.98 per cent spodumene concentrate.
Shares last traded at 2.6 cents.
And, Biome Australia (ASX:BIO) has issued the market a revenue update.
Biome surpassed $5 million in revenue across the first five months of FY24.
The company says it’s on track to meet the original FY24 guidance of $11.5 million.
Shares last traded at 12.5 cents.
